Predictive Molecular-State Modeling for Cancer Treatment Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting patient response and resistance to cancer treatment are inadequate, particularly in cases of metastasized tumors, due to the complexity of genetic variations and resistance mechanisms, which limits effective treatment strategies.
Innovation Solution
A computer-implemented method using genetic profiling of tumors from cell-free bodily fluids to generate predictive algorithms that forecast treatment outcomes based on genetic profiles and treatment histories, employing decision trees and machine learning to optimize treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If detailed studies of tumor tissue are conducted to characterize drug resistance, then measurement precision is improved, but loss of time increases due to the lengthy process of obtaining tissue samples and conducting experimental confirmation
Solution Approach 1:
The patent uses cell-free DNA as a surrogate copy of tumor genetic information, eliminating the need for invasive tissue biopsies and lengthy experimental confirmation. By analyzing circulating tumor DNA in blood samples, the system rapidly characterizes resistance mechanisms without requiring physical tumor tissue samples or time-consuming in vitro experiments.
Solution Approach 2:
The patent performs genetic profiling of cell-free DNA before treatment initiation and at early time points during treatment, enabling prediction of resistance outcomes in advance. This preliminary genetic characterization allows clinicians to select appropriate therapies and monitor resistance development proactively, rather than waiting for treatment failure and conducting retrospective tissue studies.
2Measurement precision
If genetic profiling is performed on multiple time points to track tumor evolution, then prediction accuracy is improved, but loss of time increases due to repeated sampling and analysis
Solution Approach 1:
The patent establishes continuous monitoring of tumor genetic evolution by repeatedly analyzing cell-free DNA at multiple time points throughout treatment. This longitudinal tracking captures real-time changes in tumor genotype, including emergence of resistance mutations, without interrupting treatment. The continuous nature of cell-free DNA presence in circulation enables frequent sampling without invasive procedures.
Solution Approach 2:
The patent uses sequential cell-free DNA analysis to provide feedback on treatment response and resistance development. Each new genetic profile is compared to previous profiles to detect clonal evolution and resistance mechanisms, allowing dynamic adjustment of therapy. This feedback loop enables proactive treatment modification based on real-time genetic monitoring rather than waiting for clinical deterioration.
3Measurement precision
If comprehensive genetic profiles including multiple genes are analyzed, then prediction accuracy is improved, but device complexity increases due to the sophisticated bioinformatics and machine learning required
Solution Approach 1:
The patent divides the complex task of resistance prediction into separate analytical components: (1) genetic variant detection in cell-free DNA, (2) classification of variants by functional impact, (3) integration with treatment history, and (4) machine learning-based prediction. Each component can be independently optimized and validated, reducing overall system complexity while maintaining high prediction accuracy through modular architecture.
4Ease of operation
If cell-free DNA analysis is used instead of tissue biopsies, then ease of operation is improved, but measurement precision may worsen due to lower DNA quantity and quality
Solution Approach 1:
The patent exploits the asymmetric distribution of cell-free DNA fragments in circulation, where tumor-derived fragments have distinct size and sequence characteristics compared to normal DNA. By designing enrichment strategies that target these asymmetric features (such as fragment length selection and tumor-specific mutation enrichment), the system achieves high-sensitivity detection despite the low abundance of cell-free tumor DNA in plasma.
Data Source
AI summary
A computer-implemented method for training a predictive model to predict a probability that an initial state of a subject will develop a subsequent state. The method includes receiving sequence reads, grouping the sequencing reads into families, constructing a molecular state vector for subjects, storing ordered pairs of vectors, and training the predictive model based on the ordered pairs of vectors. The system supports training the predictive model on a genetic profile of a tumor, a patient profile, and/or treatment profiles.